Viemed Healthcare Inc (VMD)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $346.72M
Last updated: Nov 17, 2026 at 4:15 PM ET
Viemed Healthcare Inc (VMD) Statistics
Viemed Healthcare (VMD) has a market cap of $346.72M and an enterprise value of $342.07M. Revenue grew 21.81% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 1.34% below the market cap, as cash exceeds debt.
| Market Cap | $346.72M |
|---|---|
| Enterprise Value | $342.07M |
| Latest price (Nov 17, 2026) | $9.07 |
Key Dates
The next earnings report is expected on Mar 2, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 2, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.1x and 2.3x. Its year-end P/E ranged from 9.9x to 50.4x from 2018 to 2025.
| P/E Ratio | 23.9x |
|---|---|
| Forward P/E | 21.7x |
| P/S Ratio | 1.1x |
| Forward P/S | 1.1x |
| P/B Ratio | 2.3x |
| P/TBV Ratio | 3.8x |
| P/FCF Ratio | 16.2x |
| P/OCF Ratio | 6.4x |
| PEG Ratio | 0.9 |
Enterprise Valuation
Counting debt and cash, the company is valued at 6.2x EBITDA and 15.9x free cash flow.
| EV / Earnings | 21.2x |
|---|---|
| EV / Sales | 1.1x |
| EV / EBITDA | 6.2x |
| EV / EBIT | 14.1x |
| EV / FCF | 15.9x |
Price Statistics
The stock is up 41.94% over 52 weeks and trades 2.37% below its 50-day average.
| Beta (1Y) | 0.46 |
|---|---|
| 52-Week Change | +41.94% |
| 1-Month Change | -5.42% |
| 3-Month Change | +1.45% |
| 6-Month Change | -5.62% |
| 5-Year Change | +68.76% |
| Total Return (1Y) | +41.94% |
| Total Return (3Y CAGR) | +5.75% |
| Total Return (5Y CAGR) | +10.25% |
| Return vs SPY (1Y) | +32.18% |
| Max Drawdown (1Y) | -30.49% |
| Max Drawdown (3Y) | -40.64% |
| Sharpe Ratio (1Y) | 0.88 |
| Correlation with SPY (1Y) | 0.15 |
| 50-Day Average | $9.29 |
| 200-Day Average | $9.67 |
| 52-Week Range | $6.18 to $12.61 |
| RSI (14 Days) | 43.4 |
| Average Volume (20 Days) | 205.98K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.25x current liabilities, and total debt is 0.03x shareholder equity.
| Current Ratio | 1.25x |
|---|---|
| Quick Ratio | 1.16x |
| Debt / Equity | 0.03x |
| Debt / EBITDA | 0.09x |
| Debt / FCF | 0.23x |
Returns and Efficiency
Return on invested capital is 11.10% over the last 12 months, against a 5-year average of 8.67%.
| Return on Equity (ROE) | 10.77% |
|---|---|
| Return on Assets (ROA) | 7.79% |
| Return on Invested Capital (ROIC) | 11.10% |
| Return on Capital Employed (ROCE) | 15.17% |
| ROE (5Y Average) | 8.91% |
| ROA (5Y Average) | 6.77% |
| ROIC (5Y Average) | 8.67% |
| Asset Turnover | 1.51x |
| Inventory Turnover | 26.92x |
| Receivables Turnover | 9.25x |
| Cash Conversion Cycle | 23 days |
Taxes
Income tax took 29.20% of pretax income over the last 12 months.
| Income Tax (TTM) | $6.67M |
|---|---|
| Effective Tax Rate | 29.20% |
Scores
VMD has an Altman Z-Score of 6.44, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 6.44 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $310.37M over the last 12 months.
| Revenue | $310.37M |
|---|---|
| Revenue Growth (YoY) | +21.81% |
| Gross Profit | $178.17M |
| Operating Income | $24.09M |
| Pretax Income | $22.83M |
| Net Income | $16.17M |
| EBITDA | $55.05M |
| EBIT | $24.31M |
| Reported EPS (TTM) | $0.38 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 72.29% of the $207.63M in total assets.
| Cash and Equivalents | $9.68M |
|---|---|
| Total Debt | $5.02M |
| Net Cash | $4.66M |
| Net Cash Per Share | $0.12 |
| Working Capital | $11.97M |
| Shareholder Equity | $150.09M |
| Book Value Per Share | $3.94 |
| Tangible Book Value | $90.06M |
| Tangible Book Per Share | $2.36 |
| Total Assets | $207.63M |
| Total Liabilities | $55.65M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $32.52M of capital spending, operating cash flow left $21.38M of free cash flow.
| Operating Cash Flow | $53.90M |
|---|---|
| Capital Expenditures | $32.52M |
| Free Cash Flow | $21.38M |
| FCF Per Share | $0.56 |
| Depreciation and Amortization | $30.73M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 7.76%, against a 5-year average of 8.03%.
| Gross Margin | 57.41% |
|---|---|
| Operating Margin | 7.76% |
| Pretax Margin | 7.36% |
| Net Margin | 5.21% |
| EBITDA Margin | 17.74% |
| EBIT Margin | 7.83% |
| FCF Margin | 6.89% |
| Gross Margin (5Y Average) | 60.45% |
| Operating Margin (5Y Average) | 8.03% |
| Net Margin (5Y Average) | 5.73% |
Growth
Revenue grew 24.87% a year over 3 years, and EPS 35.11% a year.
| Revenue Growth (3Y CAGR) | +24.87% |
|---|---|
| Revenue Growth (5Y CAGR) | +15.53% |
| EPS Growth (3Y CAGR) | +35.11% |
| EPS Growth (5Y CAGR) | -13.86% |
| FCF Growth (3Y CAGR) | +36.33% |
| FCF Growth (5Y CAGR) | -11.57% |
| Operating Income Growth (3Y CAGR) | +40.63% |
| Book Value Per Share Growth (2Y CAGR) | +11.79% |
| Tangible Book Per Share Growth (2Y CAGR) | -1.07% |
Dividends and Yields
VMD does not pay a dividend. Its free cash flow yield is 6.19%.
| Earnings Yield | 4.18% |
|---|---|
| FCF Yield | 6.19% |
| Buyback Yield | 2.24% |
| Shareholder Yield | 2.39% |
Peer Position
Against 6 similar companies, VMD has the 4th highest P/E.
P/E RatioPeer median 24.2x
P/S RatioPeer median 1.8x
ROICPeer median -9.98%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +9.94%
| P/E Ratio | 23.9x vs 24.2x median |
|---|---|
| P/S Ratio | 1.1x vs 1.8x median |
| ROIC | 11.10% vs -9.98% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +21.81% vs +9.94% median |
Analyst Forecast
Consensus estimates put revenue growth at 13.71% and EPS growth at 18.17% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +13.71% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +18.17% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About VMD
What is VMD's market cap?
Viemed Healthcare has a market cap of $346.72M. Its enterprise value, which adds debt and subtracts cash, is $342.07M.
What is VMD's P/E ratio?
Viemed Healthcare has a trailing P/E ratio of 23.9x and a forward P/E of 21.7x.
How many shares of VMD are outstanding?
Viemed Healthcare has 38.10M shares outstanding. The count is down 1.39% from a year earlier.
Does VMD pay a dividend?
No. Viemed Healthcare does not pay a dividend.
How much debt does VMD have?
Viemed Healthcare has $5.02M of total debt and $9.68M of cash and equivalents, a net cash position of $4.66M.
VMD pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors